Upgrade to SI Premium - Free Trial

Mizuho Securities Cuts Price Target on Teva Pharma (TEVA) Following Slight 4Q EPS Miss

February 12, 2016 7:33 AM
Mizuho Securities reiterated a Buy rating on Teva Pharma (NYSE: TEVA), and cut the price target to $78.00 (from $79.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Next Articles